TY - JOUR
T1 - Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib
AU - Sharma, Manish
AU - Ravandi, Farhad
AU - Bayraktar, Ulas Darda
AU - Chiattone, Alexandre
AU - Bashir, Qaiser
AU - Giralt, Sergio
AU - Chen, Julianne
AU - Qazilbash, Muzaffar
AU - Kebriaei, Partow
AU - Konopleva, Marina
AU - Andreeff, Michael
AU - Cortes, Jorge
AU - McCue, Deborah
AU - Kantarjian, Hagop
AU - Champlin, Richard E.
AU - De Lima, Marcos
PY - 2011/12
Y1 - 2011/12
N2 - Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients.
AB - Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who relapsed after HSCT with sorafenib alone (n = 8) or in combination with cytotoxic chemotherapy (n = 8). The number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission (CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients.
KW - Acute myeloid leukemia
KW - FLT3
KW - Sorafenib
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=80054771760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054771760&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2011.07.011
DO - 10.1016/j.bbmt.2011.07.011
M3 - Article
C2 - 21767516
AN - SCOPUS:80054771760
SN - 1083-8791
VL - 17
SP - 1874
EP - 1877
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 12
ER -